New Jersey critical care devices maker Ikaria Inc. is rumored to be looking for an exit, hoping to claim at least $2 billion, according to unnamed sources.
Ikaria is owned by private equity and venture capital companies including Mountain Capital LLC, ARCH Venture Partners LP and Venrock Associates LP.
The buyout rumor came from 3 anonymous sources cited by Reuters, which reported that Ikaria over the next couple of years faces the expiration of several of its key patents, amping up it vulnerability to rival companies. Ikaria posted $361 million in annual revenue last year, according to the news service.
Ikaria is perhaps best known for its neonatal drug Inomax, which help oxygenate blood in babies with severe breathing problems, but the company also has a portfolio of critical care devices including drug-delivery and respiratory care devices.